AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01315470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neupogen administration for women with recurrent IVF failure
Description: neupogen 300 mcg - twice
Study NCT02727153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra E.R.A.S.
Study NCT02727153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic E.R.A.S.
Study NCT01893476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation educational programme
Description: Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
Study NCT03157596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health Educational Program for Caregivers of Children with developmental disabilities
Description: Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD \& methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
Study NCT02740790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
Study NCT02740790 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
Study NCT02374619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplement Resoferon Ferrous Sulfate
Description: Oral supplementation with one tablet of iron supplement \[Resoferon Ferrous Sulfate 125 (37) mg\]
Study NCT02374619 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03627078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor interference therapy
Study NCT03627078 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Relaxation exercises
Description: In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
Study NCT01889732 — intervention group
Intervention type: DEVICE
Intervention: ROTEM
Study NCT03513471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
Study NCT03513471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anakinra Matching Placebo
Description: A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
Study NCT03513471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermatophagoides Farinae
Description: Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
Study NCT00568893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drotrecogin alfa (activated)
Study NCT04705532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Multi-channel tDCS will be applied over the executive network for 20 minutes at 4mA
Study NCT04705532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
Study NCT04705532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Subjects will listen to their preferred music for 20 minutes
Study NCT04705532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Subjects will listen to a white noise for 20 minutes
Study NCT03488563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B244
Description: B244 Suspension
Study NCT03488563 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Suspension
Study NCT00888498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Passive Positioning
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
Study NCT00888498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Velocity, Low-Amplitude Stretch
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
Study NCT00888498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow, Mobilization Stretch
Description: With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
Study NCT03592849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UC-MSCs therapy
Description: After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
Study NCT01204918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole 100mg PO
Study NCT01204918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01204918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT01088711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Once-weekly 50 mg capsule
Study NCT01088711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-weekly placebo capsule
Study NCT04539548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza Ophthalmic Insert
Description: 0.4mg insert for intracanalicular use
Study NCT04539548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate ophthalmic suspension USP 1%
Description: 1 drop at end of surgery, followed by:~1 drop 4 x QID for one week.~1 drop 3 x QID for one week.~1 drop BID for one week.~1 drop QD for one week
Study NCT02025933 — intervention group
Intervention type: OTHER
Intervention: Salmon Group
Description: The children are advised to eat at least 75g of salmon per serving, but no more than 150g
Study NCT02025933 — intervention group
Intervention type: OTHER
Intervention: Cod Group
Description: The children are advised to eat at least 75g of cod per serving, but no more than 150g
Study NCT02025933 — intervention group
Intervention type: OTHER
Intervention: Meat Group
Description: The children are advised to eat at least 75g of meat per serving, but no more than 150g
Study NCT06365190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: During treatment, the patient underwent cTBS targeting the left SMA for 14 consecutive days. Each treatment day comprised three rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
Study NCT06365190 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacotherapy（antiparkinsonian drugs）
Description: Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
Study NCT03188523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8504
Description: After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
Study NCT04640740 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hip arthroplasty
Description: two different approaches of total hip arthroplasty
Study NCT03122470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI guided biopsy
Description: The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
Study NCT02788188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-301
Description: SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
Study NCT02788188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal (9%) Saline
Description: Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
Study NCT03961750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTAGO
Description: 12 Week exercise class programme
Study NCT01887288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 650 mg/m\^2 PO b.i.d.
Study NCT01887288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.25 mg once daily
Study NCT04403165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nocturnal polysomnography (NPSG)
Description: Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
Study NCT04403165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (LP)
Description: Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
Study NCT04403165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB)
Description: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
Study NCT04403165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychomotor Vigilance Task (PVT)
Description: Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
Study NCT03122470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRUS biopsy
Description: The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
Study NCT03004053 — intervention group
Intervention type: DEVICE
Intervention: Reflectance Confocal Microscopy (RCM) endoscope device
Study NCT04186104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine diagnostic process
Description: Patients follow the procedures of registration, waiting, attendance, waiting, examination, waiting, attendance.
Study NCT04186104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted diagnosis process
Description: Patients follow the procedures of registration, AI recommended examination items, Self-service medical history collection ,examination, waiting, AI-assisted attendance.
Study NCT03799913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-MESO CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express anti-MESO CARs
Study NCT02348008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
Study NCT02348008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
Study NCT03799913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/d
Study NCT03799913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300mg/m2/d
Study NCT06336187 — intervention group
Intervention type: OTHER
Intervention: active surveillance
Description: Follow-up visits will be scheduled 3 (optional) and 6 months after diagnosis, every 6 months up to 3 years and yearly thereafter.
Study NCT02348008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK-3475
Description: Arm B: Phase II Treatment: 200mg IV
Study NCT02348008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Arm B: Phase II Treatment: administered at the maximum safe dose of 10mg or 15mg as established in the Phase 1b dose escalation cohort study.
Study NCT03260790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV13
Description: Single 0.5 ml dose of PCV13 administered via intramuscular injection
Study NCT03260790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPSV23
Description: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
Study NCT03260790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
Study NCT02164318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip training
Study NCT02164318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Study NCT04321083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: INVOS
Description: INVOS monitoring brain o2 saturation
Study NCT02253381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right
Description: Right lateral decubitus position during spinal anesthesia
Study NCT02253381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left
Description: Left lateral decubitus position during spinal anesthesia
Study NCT02335346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT01548768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF inhibitors
Description: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.
Study NCT01548768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
Study NCT01548768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
Study NCT06336187 — intervention group
Intervention type: GENETIC
Intervention: molecular investigation
Description: Transcriptomic analysis of tissues
Study NCT04454034 — intervention group
Intervention type: PROCEDURE
Intervention: arthroscopic synovectomy
Description: arthroscopic synovectomy
Study NCT04268537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody+standard treatment
Description: After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT04268537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin+standard treatment
Description: Thymosin 1.6 mg sc qd, last for 5 days. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT02806271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Postponement
Description: In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate.
Study NCT02806271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Worry Monitoring
Description: For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
Study NCT02806271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Worry Monitoring
Description: For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
Study NCT04070248 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04268537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Study NCT04539483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDIT101 (blinded therapy)
Description: Patients will be treated with with topical HDIT101 (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Study NCT04539483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded therapy)
Description: Patients will be treated with with topical placebo (twice daily for 2 days). Blinded study drug will be applied to the first 2 lesions occuring in the treatment phase.
Study NCT04539483 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo documentation of orolabial herpes lesions
Description: Patients will be asked to document their orolabial lesions with photos by using their smart phone
Study NCT04539483 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Photo documentation of orolabial herpes lesions
Description: Patients will be asked to document their orolabial lesions with photos by using their smart phone